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Tumor necrosis factor-a (TNF-a) and ®broblast growth
factor-2 (FGF-2 or bFGF) are potent stimulators of
angiogenesis. TNF-a, but not FGF-2, can induce the
expression of vascular cell adhesion molecule-1
(VCAM-1) on the surface of endothelial cells. The sol-
uble form of VCAM-1 has recently been demonstrated
to function as an angiogenic mediator. Here we dem-
onstrate that monoclonal antibodies directed against
VCAM-1 or its a4 integrin counter-receptor inhibited
TNF-a-induced endothelial cell migration in vitro. An-
giogenesis induced in vivo in rat corneas by TNF-a was
inhibited by a neutralizing antibody directed against
the rat a4 integrin subunit. A peptide antagonist of the
a4 integrins blocked TNF-a-induced endothelial cell
migration in vitro and angiogenesis in rat corneas in
vivo. No inhibition by the antibodies or peptide antag-
onist was observed either in vitro or in vivo when FGF-
2 was used as the stimulus. The peptide antagonist did
not inhibit TNF-a binding to its receptor nor did it block
the function of avb3, an integrin previously implicated
in TNF-a and FGF-2 mediated angiogenesis. These re-
sults demonstrate that angiogenic processes induced
by TNF-a are mediated in part by a4 integrins possibly
by a mechanism involving the induction of soluble
VCAM-1.
(Received 30 April 1998; accepted 13 August 1998)
Introduction
Angiogenesis is the growth of new blood vessels
from preexisting vessels. This process is essential
for proper development and wound healing, yet is
also characteristic of certain pathological condi-
tions including arthritis, psoriasis, retinopathy
and tumor growth.1 TNF-a is one of the primary
angiogenic mediators derived from activated
macrophages and as such is thought to play a key
role in chronic in¯ammatory diseases such as
rheumatoid arthritis.2
TNF-a was ®rst identi®ed as the substance
mediating necrosis of certain tumors that were
treated with endotoxin.3 Although TNF-a in-
hibits endothelial cell growth in vitro,4,5 it has
been shown to induce endothelial cell migration
in vitro6 and cause angiogenesis in vivo when im-
planted into corneas or choriallantoic mem-
branes.5,6 It has been proposed that the
mechanism of TNF-a mediated angiogenesis may
be indirect and may depend on the synthesis of
secondary mediators including prostaglandins,
platelet activating factor, the Eck receptor ligand
B61, and more recently interlukin-8, vascular
endothelial growth factor (VEGF) and FGF-2.7±10
Friedlander et al.11 demonstrated that angio-
genesis induced by TNF-a or FGF-2 is depen-
dent on the integrin avb3 whereas that mediated
by two other angiogenic mediators, VEGF
and transforming growth factor-a, is avb5 de-
pendent.
TNF-a can induce the expression of cell
adhesion molecules, including VCAM-1 and
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E-selectin, on the surface of endothelial cells.12,13
Soluble forms of VCAM-1 (sVCAM-1) and
E-selectin have recently been demonstrated to
function as angiogenic mediators.14 The a4 inte-
grins serve as counter-receptors for VCAM-1.15,16
Expressed abundantly on the surface of leukocytes,
the a4 integrin subunit has been detected at lower
levels on the surface of endothelial cells as
well.14,17 In fact, neutralizing antibodies directed
against the a4 integrin receptors inhibit the mi-
gration of endothelial cells toward sVCAM-1.14
We have used endothelial cell migration assays
and an in vivo model of angiogenesis to demon-
strate that TNF-a-induced angiogenesis is de-
pendent, in part, on functions mediated by a4
integrins. These data implicate sVCAM-1 as a
potential secondary mediator in angiogenic pro-
cesses induced by TNF-a.
Materials and methods
Materials. Recombinant human TNF-a and re-
combinant human FGF-2 were purchased from
R&D Systems, Inc. (Minneapolis, MN) and Up-
state Biotechnology (Lake Placid, NY), respec-
tively. Anti-human VCAM-1 was from Genzyme
(Cambridge, MA) and anti-rat a4 (TA-2) was
from Seikagaku America, Inc. (Rockville, MD).
Anti-human a4 (L25) and anti-human b1
(mAb13) were from Becton Dickinson (San
Jose, CA). Anti-human b1 (33B6) and anti-Leu
13 (35F9) were generated and maintained in the
McIntyre laboratory. Anti-CD3 mAb OKT3 was
obtained from the American Type Culture
Collection (Rockville, MD). Anti-human avb3
(23C6) was from Pharmingen (San Diego, CA).
Anti-human avb5 (P1F6) ascites and the cyclic
RGD peptide (GPenGRGDSPCA) were from Life
Technologies (Grand Island, NY). FITC-conju-
gated goat anti-mouse IgG was obtained from
Organon Teknika Corp. (West Chester, PA).
Human plasma vitronectin was purchased from
Sigma Chemical Co. (St. Louis, MO) and BSA
fraction V was from Calbiochem (LaJolla, CA).
The a4 integrin antagonist peptide, TBC772
(CWLDVC cyclic disul®de), and the scrambled
control peptide, TBC1194 (CDLVWC, cyclic
disul®de), have been previously described.18
Cells. Human umbilical vein endothelial cells
(HUVEC) were purchased from Cascade Biolog-
ics, Inc. (Portland, OR) and maintained on gelatin
coated plates in medium 199 supplemented with
15% FBS and 50 lg/ml endothelial mitogen
(Biomedical Technologies Inc., Stoughton, MA)
at 37°C in 5% CO2. HL-60 cells (human pro-
myelocytic leukemia) were obtained from the
American Type Culture Collection (Rockville,
MD) and maintained in RPMI 1640 supple-
mented with 10% FBS at 37°C in 5% CO2.
Animals. Male Sprague-Dawley rats (300 g) were
purchased from Harlan (Indianapolis, IN).
Housing and anesthesia concurred with the
guidelines established by the University of Texas
Health Science Center Institutional Animal
Welfare Committee, in accordance with the
Public Health Service Guide for the Care and Use
of Laboratory Animals, United States Department
of Agriculture regulations, and the American
Veterinary Medicine Association's Panel on Eu-
thanasia guidelines. Rats were housed individu-
ally, fed standard rat chow (Standard Laboratory
Rodent Diet No. 5001; Ralston Purina, Rich-
mond, IN) and water ad libitum, and were on a 12
hour light/dark cycle.
Migration assays. Assays were carried out in a 48-
well chamber (NeuroProbe, Cabin John, MD)
using collagen coated polycarbonate ®lters fol-
lowing procedures similar to those previously
described.19 Brie¯y, polycarbonate ®lters (8 lm
pore size; Poretics Corp., Livermore, CA) were
treated with 0.5 M acetic acid overnight, rinsed
with distilled water, and incubated for 48 h at
room temperature with 10 lg/ml collagen (Vit-
rogen 100; Cetrix Laboratories; Palo Alto, CA).
Filters were air dried prior to placing into the
chamber. Subcon¯uent HUVEC (passage 1±4)
were harvested with 0.05% trypsin/EDTA, wa-
shed with M199 containing 10% fetal calf serum
and resuspended in M199 containing 0.1% FCS at
5 ´ 105 cells/ml. TNF-a at 50 ng/ml or FGF-2 at
10 ng/ml in M199/0.1% FCS was placed in the
bottom wells of the chamber and 150 ll of
HUVEC (75,000 cells) were placed in the upper
wells. Antibodies (10 lg/ml) or peptides (10 lM)
were added to both the top and bottom chambers.
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The chamber was incubated for 4 h at 37°C in a
5% CO2 incubator. Solution in the top wells was
aspirated and nonmigrated cells were removed
from the ®lter with a wet cotton swab. Migrated
cells were ®xed in 100% ethanol for 30 min at
room temperature and stained with a modi®ed
Wright-Giemsa stain (Diff-Quik, Baxter Diag-
nostics, Chicago, IL). Migrated cells were counted
at 400 ´ magni®cation in four random ®elds per
well. Each treatment group was performed in
triplicate wells. Statistical analysis of the data was
performed using a paired Student's t-test with
p < 0.05 considered statistically signi®cant.
Flow Cytometry. HUVEC were harvested as de-
scribed above and resuspended in RPMI 1640
supplemented with 10% FCS (3 ´ 106 cells/ml).
mAbs (0.1 lg/ml) were added and incubated for
30 min at room temperature. Cells were washed
twice with PBS containing 1% BSA and incu-
bated with goat anti-mouse FITC for 30 min at
room temperature. Cells were washed with PBS
and analyzed in an EPICS Pro®le ¯ow cytometer
(Coulter Corp., Hialeah, FL). At least 10,000
events were analyzed for every test.
Quanti®cation of soluble VCAM-1. Con¯uent
monolayers of HUVEC in 35 mm plates were
treated with 50 ng/ml TNF-a or 10 ng/ml FGF-2
in M199/0.1% FCS for 4 h at 37°C. Media was
collected, centrifuged for 5 min at 1000 ´ g, and
concentrated using Centricon-3 ®lters (Amicon,
Beverly, MA). Samples were assayed for the
presence of human soluble VCAM-1 using an
immunoassay kit (R&D Systems, Minneapolis,
MN) according to the manufacturer's instructions.
Corneal angiogenesis assays. Assays were per-
formed similarly to those previously described.6
Pellets were made by mixing equal volumes of
TNF-a or FGF-2 (300 ng in PBS containing
0.1% BSA) and a 12% solution of Hydron (In-
terferon Sciences, New Brunswick, NJ) in ethanol.
Antibodies (1.75 lg/pellet) or peptides (100 ng/
pellet) were added directly to the cytokine/hydron
solution. Five ll were placed on the ends of 2 mm
diameter te¯on rods and allowed to dry for
30 min in a cell culture hood. Pellets were im-
planted in the corneas of 300±400 g Sprague-
Dawley rats approximately 1 mm from the lim-
bus. After 7 days, rats were euthanized with CO2,
the vasculature perfused with buffer (PBS con-
taining 10 U/ml heparin) followed by colloidal
carbon, and eyes excised and ®xed in 10% for-
malin.
TNF-a receptor assay. Anti-Human TNF Recep-
tor (p55) IgG (Austral Biologics, San Ramon, CA)
was coated onto Immulon-4 plates at 1 lg/well in
PBS overnight at 4°C. Wells were washed three
times with PBS containing 0.1% Tween-20 fol-
lowed by three washes with PBS. Wells were
blocked with 1% BSA in PBS for 1 h at 22°C and
then washed as described above. Recombinant
human TNF-a receptor extracellular domain
(Austral Biologics) was coated onto the wells at
10 ng/well in PBS overnight at 4°C. Wells were
washed, blocked and rewashed as described above.
125I-TNF-a (Biomedical Technologies Inc.,
Stoughton, MA) in PBS containing 0.1% BSA
and 25 mM HEPES was added to the wells at a
concentration of 300 pg (2 ´ 104 cpm)/well. In
certain wells, unlabeled TNF-a (300 ng/well,
PeproTech Inc., Rocky Hill, NJ) or TBC772
(1 mM) were also added. Plates were incubated for
90 min at 22°C and washed three times with
PBS. Wells were separated, placed in vials con-
taining scintillation ¯uid and counted using a
Beckman LS6000TA scintillation counter.
avb3 assay. Human plasma vitronectin was
coated onto 96-well Probind plates at 5 lg/ml in
TBS (50 mM Tris, pH 7.5, 150 mM NaCl) for
16 h at 4°C. Control wells were coated with the
same concentration of BSA in TBS. Plates were
washed three times with TBS, blocked with TBS
containing 2% BSA at room temperature for 4 h,
then washed three more times with TBS prior to
assay. HUVEC grown to con¯uency were har-
vested as described above and resuspended in
M199 containing 0.1% BSA. Cells were ¯uores-
cently labeled with calcein AM (Molecular Probes,
Eugene, OR) and resuspended at 4 ´ 106 cells/ml
in M199, 0.1% BSA, 1 mM MnCl2. Calcein-AM
is a non-¯uorescent substrate taken up and pro-
cessed by viable cells to yield a ¯uorescent,
membrane impermeable product. Labeled HU-
VEC were added to the wells (2 ´ 105 cells/well)
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and incubated at 37°C for 30 min. Following
three washes with TBS containing 1 mM CaCl2,
1 mM MgCl2, and 1 mM MnCl2, adherent cells
were lysed with 50 ll of 1% Nonidet P-40 in
50 mM Tris, pH 7.5 and 5 mM EDTA. The
number of cells bound was quantitated using a
Millipore Cyto¯uor 2350 ¯uorometer (Millipore
Corp., Bedford, MA). Antibodies (10 lg/ml) or
ascites (1:100 dilution) were preincubated with
labeled HUVEC for 20 min at 37°C prior to
addition of cells to the wells. Peptide inhibitors at
the indicated concentrations were mixed with
HUVEC immediately prior to addition of cells to
the wells.
E-selectin assay. Assays were performed as pre-
viously described.20 Brie¯y, 10 ll of ¯uorescently
labeled HL-60 cells (107 cells/ml) were added to
wells of a 96 well plate that had been previously
blocked with 3% BSA. This was followed by the
addition of 10 ll of magnetic beads (4 ´ 106
beads/ml) coated with an E-selectin IgG fusion
protein. After a 10 min incubation at room
temperature, the beads were placed on a magnetic
seperator and unbound cells were removed with
two washes of the wells with PBS. Bound cells
were lysed with a 1% NP-40 solution in PBS and
quantitated using a Millipore Cyto¯uor 2350
¯uorimeter. The TBC772 peptide was added to
the cells immediately prior to the addition of
beads. Binding of HL-60 cells to E-selectin beads
previously has been shown to be blocked by sLex
tetrasaccharide and anti-sLex antibodies.20
Results
Inhibition of a4 integrins or VCAM-1 inhibits
TNF-a) but not FGF-2-induced endothelial cell
migration. HUVEC migration across collagen
coated polycarbonate membranes was measured in
response to the cytokines TNF-a or FGF-2. The
optimal doses for HUVEC migration were de-
termined to be 50 ng/ml and 10 ng/ml for TNF-
a and FGF-2, respectively (data not shown).
Stimulation with cytokines resulted in an 1.5±
2.0 fold increase in cell migration as compared to
unstimulated controls (Figures 1A±C). For ease of
comparison, the y-axis of each graph in Figures
1A±C spans an equal-fold range of cell counts.
Figure 1. TNF-a- but not FGF-2-induced HUVEC migration is
inhibited by anti-VCAM-1, anti-a4 or a peptide antagonist of a4
integrins. HUVEC migration was measured in a 48-well cham-
ber using collagen-coated polycarbonate ®lters in the absence
()) and presence (+) of TNF-a or FGF-2. Cytokine-induced
migration was determined in the presence of: (A) anti-VCAM-1
or IgG1 isotype control antibodies, (B) anti-a4 or IgG2b isotype
control antibodies, (C) an a4 integrin peptide antagonist
TBC772 or a scrambled peptide control TBC1194. Migrated
cells were counted in four random ®elds per well and each
treatment group was performed in triplicate wells. Data are
presented as the average number of cells counted per ®eld
 S.E.M. In each case, the y-axis represents a two-fold range
of cell counts. Statistical analysis of the data was performed
using a paired student's t-test with p < 0.05 considered statis-
tically signi®cant (n.s.  not signi®cant).
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TNF-a-induced migration was inhibited greater
than 75% in the presence of an anti-VCAM-1
antibody (p  0.007 relative to an isotype
control) (Figure 1A). Similarly, HUVEC migra-
tion in response to TNF-a was completely in-
hibited in the presence of an anti-a4 antibody
(p  0.025 relative to an isotype control) (Fig-
ure 1B). Signi®cant inhibition of migration also
was demonstrated with a cyclic peptide antagonist
of a4 integrins, TBC772,18 included in the assay
at a concentration of 10 lM (p  0.023 relative
to a scrambled peptide control TBC1194) (Fig-
ure 1C). In contrast, no signi®cant inhibition of
FGF-2-induced HUVEC migration was seen rel-
ative to controls in the presence of anti-VCAM-1,
anti-a4 or TBC772 (Figures 1A±C).
HUVEC treated with TNF-a generate sVCAM-1.
The above results suggested that HUVEC mi-
gration induced by TNF-a may be mediated by
the interaction between VCAM-1 and its a4
integrin counter-receptor. TNF-a induces
VCAM-1 expression on the surface of endothelial
cells12 whereas FGF-2 does not.21 Since a soluble
form of VCAM-1 previously has been demon-
strated to induce endothelial cell migration,14
levels of sVCAM-1 in culture media from
cells treated with TNF-a were determined. Con-
¯uent monolayers of HUVEC in 35 mm plates
were treated with cytokines under the same con-
ditions used in the migration assays (4 h at 37°C
with 50 ng/ml TNF-a or 10 ng/ml FGF-2).
Culture media were collected and assayed for the
presence of sVCAM-1 by ELISA. No sVCAM-1
was detected in media derived from untreated
cells or cells treated with FGF-2. sVCAM-1 was
detected in media from TNF-a treated cells
at a concentration of 1.76  0.06 ng/ml or
20 pM.
Although a4 integrin has previously been re-
ported to be expressed on the surface of HU-
VEC,14,17 the presence of a4 on the HUVEC used
for the experiments described herein was veri®ed
by ¯ow cytometry. Figure 2 shows the relative
¯uorescence intensity pro®les obtained with
HUVEC in the presence of various antibodies.
The pro®les of HUVEC with mAbs directed
against the leukocyte antigens CD3 (OKT3)
(2.8% positive cells) or Leu 13 (35F9) (3.1%
positive) served as negative controls and were es-
sentially indistinguishable from that of FITC
alone (2.2% positive). In contrast, there was a
signi®cant shift in the pro®le with a mAb against
the a4 integrin subunit (L25) (28.1% positive).
The anti-b1 mAb, 33B6, was used as a positive
control (84.2% positive). These results demon-
strate that a4 integrin receptors are indeed ex-
pressed on the surface of the HUVEC that were
used for the experiments detailed above.
Inhibition of a4 integrins inhibits TNF-a) but not
FGF-2-induced angiogenesis in the rat cornea.
The rat corneal model was used to determine if a4
integrins were involved in TNF-a-induced an-
giogenesis in vivo. Hydron pellets containing cy-
tokines and either an anti-rat a4 integrin
monoclonal antibody or an IgG1 control were
implanted into rat corneas and analyzed 7 days
later following perfusion of the blood vessels with
India ink. The anti-a4 antibody blocked the an-
giogenic response induced by TNF-a in all six
corneas tested (0 of 6 corneas were positive)
whereas the control IgG1 had a negligible effect
on the angiogenic response (7 of 9 corneas posi-
Figure 2. HUVEC express a4 integrin. HUVEC were incubat-
ed with anti-CD3 mAb (OKT3), anti-b1 mAb (33B6), anti-a4
mAb (L25), anti-Leu 13 mAb (35F9), or no primary mAb (FITC).
Binding of mAbs to HUVEC was determined by FACS analysis.
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tive) (Figure 3A, Table 1). Similar results were
obtained with the a4 peptide antagonist and
control; angiogenesis induced by TNF-a was ef-
fectively inhibited with TBC772 (0 of 8 corneas
positive) but not with the control peptide
TBC1194 (7 of 8 corneas positive) (Figure 4A,
Table 1). Conversely, neither the anti-rat a4 an-
tibody nor TBC772 were effective inhibitors of
angiogenesis induced by FGF-2 (Figures 3B, 4B
and Table 1). The antagonist peptide did not
prevent angiogenesis by non-speci®cally inhibi-
ting TNF-a binding to its receptor; since no in-
hibition was detected in a TNF-a receptor
binding assay at concentrations as high as 1 mM
TBC772 (Figure 5A).
TNF-a-induced angiogenesis has been shown
to be dependent on the integrin avb3.11 Al-
though the peptide TBC772 is selective for the
a4 integrins over a5b1,18 an assay was devel-
oped to determine if the peptide demonstrated
any activity towards avb3. The binding of HU-
VEC to human plasma vitronectin was deter-
mined to be inhibited by an anti-avb3 antibody
(p  0.0008) and completely eliminated by a
cyclic RGD peptide speci®c for the vitro-
nectin receptor at a concentration of 10 lM
(p  0.0001) (Figure 5B). No inhibition of
avb3-dependent binding of HUVEC to vitro-
nectin was detected in the presence of 1 mM
TBC772 (Figure 5B).
Finally, TNF-a induces the expression of
E-selectin on the surface of endothelial cells.13 A
soluble form of E-selectin has also been demon-
strated to function as an angiogenic mediator with
sLex being the likely counter-receptor.14 As an
additional analysis of speci®city, TBC772 at
1 mM had no effect on the binding of sLex-ex-
pressing HL-60 cells to puri®ed E-selectin (Fig-
Figure 3. Angiogenesis induced in rat corneas by TNF-a is
inhibited by an anti-rat a4 antibody. Hydron pellets containing
300 ng of TNF-a (A) or FGF-2 (B) were implanted into the
corneas of Sprague-Dawley rats. Pellets also contained anti-rat
a4 antibody or an IgG1 isotype control antibody (1.75 lg/pellet)
as indicated. Seven days later, rats were perfused with colloidal
carbon and the eyes excised and ®xed.
Table 1. Results of rat cornea angiogenesis model using in-
hibitors of a4 integrins
Treatment Cytokine (# of positive corneas/
total # of corneas tested)
TNF-a FGF-2
Anti-a4 mAb 0/6 6/6
IgG1 control 7/9 5/5
TBC772 0/8 7/8
TBC1194 7/8 7/8
Figure 4. Angiogenesis induced in rat corneas by TNF-a is
inhibited by a peptide antagonist of a4 integrins. Hydron pellets
containing 300 ng of TNF-a4 (A) or FGF-2 (B) were implanted
into the corneas of Sprague-Dawley rats. Pellets also contained
a peptide antagonist of a4 integrins, TBC772, or a scrambled
peptide control, TBC1194 (100 ng/pellet) as indicated. Seven
days later, rats were perfused with colloidal carbon and the
eyes excised and ®xed.
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ure 5C). The binding of the HL-60 cells to the E-
selectin in this assay format has previously been
shown to be blocked by sLex tetrasaccharide and
anti-sLex antibodies.20
A summary of the activity of TBC772 in
various adhesion assays is given in Table 2. Al-
though the peptide antagonist is quite selective
for the a4 class of integrins, the possibility
remains that it may be active in the migration and
corneal assays by interacting with other endothe-
lial cell adhesion molecules or receptors yet to be
analyzed.
Discussion
TNF-a is a pluripotent mediator effecting several
cellular processes including adhesion, migration,
angiogenesis and apoptosis.6,12,22 The angiogenic
potential of TNF-a may be due to the generation
Figure 5. TBC772 does not inhibit ligand binding to the TNF
receptor, avb3, or E-selectin. All assays were performed as
described in `Materials and methods'. Statistical analysis of the
data in Figures 5A and 5B was performed using a paired Stu-
dent's t-test. Treatment groups with p values less than 0.05
when compared to untreated controls were considered statis-
tically signi®cant and denoted with an asterisk (*). (A) [125I]
TNF-a binding to recombinant human TNF-a receptor extra-
cellular domain was measured in the absence or presence of
unlabeled TNF-a or 1 mM TBC772. TNF-a binding is expressed
as the average cpm  SD of duplicate wells. (B) Binding of
¯uorescently labeled HUVEC to human plasma vitronectin im-
mobilized on a 96 well plate was measured in the absence or
presence of 10 lM RGD peptide (GpenGRGDSPCA), 1 mM
TBC772, anti-avb3 (10 lg/ml), anti-b1 (10 lg/ml), anti-avb5
ascites (1:100 dilution) or the proper isotype controls. The data
are expressed as % adhesion relative to untreated HUVEC
bound to vitronectin (typically 1600 cells bound/mm2) versus
bound to BSA (typically <10 cells bound/mm2). The data rep-
resent the average % adhesion  SD of triplicate wells. (C)
Binding of ¯uorescently labeled HL-60 cells to an E-selectin-IgG
fusion protein bound to magnetic beads was measured in the
absence or presence of 1 mM TBC772. Background ¯uores-
cence of control mock beads (10% of E-selectin beads) was
subtracted from all values. The binding of the HL-60 cells to the
E-selectin in this assay format previously has been shown to be
blocked by sLex tetrasaccharide and anti-sLex antibodies.20
The data represent the average number of cells bound per well
 SD of duplicate wells.
Table 2. Activity of TBC772 in cell adhesion assaysa





avb3/Vitronectin >1000 This paper
sLex/E-selectin >1000 This paper
a The cell adhesion assays measure the binding of integrin- or
sLex -expressing cell lines to puri®ed forms of the counter-re-
ceptors. All cell lines and counter-receptors are of human origin
except the a4b7-expressing cell line and the MAdCAM-1 which
are both of murine origin. IC50 values represent the con-
centration of compound required for inhibition of maximal cell
binding by 50%.
b
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of secondary mediators, including prostaglan-
dins,7 platelet activating factor,8 the ligand for
the Eck receptor tyrosine kinase, B619 as well as
interlukin-8, VEGF and FGF-2.10 The data pre-
sented here suggest that sVCAM-1 may also play
a key role in TNF-a-induced angiogenesis.
Using endothelial cell migration assays as well
as a rat corneal angiogenesis assay, we have dem-
onstrated a role for the VCAM-1/a4 integrin
pathway in TNF-a-mediated angiogenesis. HU-
VEC treated with TNF-a generated concentra-
tions of sVCAM-1 (20 pM) previously shown to
induce signi®cant levels of endothelial cell mi-
gration.14 Antibodies directed against VCAM-1
and the a4 integrin subunit signi®cantly inhib-
ited the migration of HUVEC across collagen
coated ®lters in response to TNF-a. In vivo, anti-
bodies directed against rat a4 integrin effectively
blocked TNF-a-induced angiogenesis in rat cor-
neas. A peptide antagonist selective for the a4
integrins was also found to inhibit both HUVEC
migration in vitro and corneal angiogenesis in vivo
mediated by TNF-a. These data support the hy-
pothesis that TNF-a can mediate angiogenic
processes by inducing the production of sVCAM-1
from endothelial cells which can then function as
an angiogenic stimulus via interaction with an a4
integrin counter-receptor on the endothelium.
Integrins, including avb3, have been clearly
linked to TNF-a-induced angiogenesis.11 How
might the a4 integrins also be involved in regu-
lating this process? sVCAM-1 binding to a4
integrin receptors on endothelial cells may lead to
integrin-dependent signaling pathways regulating
chemokinetic or chemotactic mechanisms. Here
we show that inhibitors of the a4 integrins can
inhibit the migration of HUVEC across collagen
coated membranes. This class of integrins do not
bind collagen suggesting an indirect role for the
a4 integrins in this process. Recent reports have
demonstrated that the engagement of one integrin
can regulate the function of another in several
diverse settings.23±27 Antibodies to avb3 have
been shown to block a5b1-dependent phagocy-
tosis.23 T cell coactivation induced by either b2 or
b7 integrins could be inhibited by an anti-b1
antibody.24 Engagement of aIIbb3 inhibited the
adhesive functions of the integrins a2b1 or a5b1
in transfected chinese hamster ovary cells.25 Fi-
nally, ligation of LFA-1 on T-cells was found to
regulate a4b1 and a5b1-mediated adhesion.26
Migration of endothelial cells, a critical compo-
nent of angiogenesis, is a complex process in-
volving a series of integrin-mediated adhesion and
de-adhesion events. Engagement of a4 integrins
by sVCAM-1 may lead to cross-talk with other
key integrins and play a role in coordinating these
events. In fact, cross-talk between avb3 and a4b1
has recently been demonstrated in the regulation
of lymphocyte migration on VCAM-1.27
Angiogenesis is also characterized by the pro-
duction and activation of proteinases. Huhtala
et al.28 have demonstrated in rabbit synovial
®broblasts that the ligation of a4b1 can regulate
the expression of matrix metalloproteinases in-
duced by the interaction of the integrin a5b1
with ®bronectin. Additionally, TNF-a induces
the expression of urokinase plasminogen activator
by endothelial cells which may promote angio-
genesis.29 The urokinase receptor has been dem-
onstrated to associate with and regulate the
function of certain integrins.30 Reciprocally,
integrins associated with the urokinase receptor, a
glycosyl-phosphatidylinositol-linked protein, may
serve as a means for urokinase receptor signal
transduction. In this regard, it is important to
note that it has yet to be determined if a4 inte-
grins are associated with the urokinase receptor on
endothelial cells. At the level of migration and
proteolysis, the a4 integrins may be involved at
several key steps in regulating angiogenesis in-
duced by TNF-a. Further research is required to
dissect the molecular details of such a mechanism.
The a4 integrins and/or their ligands have
been implicated in several in¯ammatory disease
states.31 Monoclonal antibodies to the a4 subunit
have proven to be effective treatments in animal
models of asthma,32 multiple sclerosis,33 diabe-
tes,34,35 in¯ammatory bowel disease,36 coronary
allograft rejection37 and rheumatoid arthritis.38,39
Presumably these treatments have been successful
by either preventing the adhesion and subsequent
migration of in¯ammatory cells or by inhibiting
activation of cell types critical for the progression
of the in¯ammatory cascade. The data reported
here suggest an additional mechanism by which
an a4 integrin antagonist may be functioning in
those in¯ammatory diseases that contain an an-
P. Vanderslice et al.
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giogenic component. For example, rheumatoid
arthritis is characterized not only by in®ltration of
in¯ammatory cells into the synovial tissue but
also by proliferation and neovascularization of
cells lining the synovium.40 TNF-a has been re-
ported to be one of the primary angiogenic me-
diators derived from monocytes/macrophages
obtained from rheumatoid synovial tissue2 and
treatment of patients with recombinant soluble
TNF-a receptor has been associated with im-
provement in the symptoms of rheumatoid ar-
thritis.41 The expression levels of VCAM-1 have
been demonstrated to be upregulated in rheu-
matoid synovium.42,43 Elevated levels of sVCAM-
1 have been detected in the plasma and synovial
¯uid from arthritic patients.44,45 Interestingly,
the angiogenic potential of human rheumatoid
synovial ¯uid as measured in the rat corneal
model could be attenuated with antibodies di-
rected against VCAM-1.14 These results suggest
that the production of sVCAM-1 by TNF-a may
play a prominent role in the progression of an-
giogenic, in¯ammatory diseases.
Conclusion
TNF-a-induced endothelial cell migration in vitro
and angiogenesis in rat corneas in vivo were in-
hibited by antibodies or by a small peptide an-
tagonist directed against the VCAM-1/a4
integrin adhesion pathway. These data support a
mechanism by which TNF-a induces angiogenesis
via the generation of sVCAM-1 which then acts
through an a4 integrin receptor expressed on the
endothelial cell surface. Our results extend the
®ndings of Koch et al.14 implicating sVCAM-1 as
an angiogenic mediator and strengthen the link
between in¯ammatory cytokines, cellular adhe-
sion, and angiogenesis.
Acknowledgements
The authors thank David K. Wooten and Kurt
Berens for assistance in preparation of certain
®gures for the manuscript and Dr. Richard Dixon
and Dr. Ajay Rege for critical review of the
manuscript.
References
1. Folkman J. Angiogenesis in cancer, vascular, rheu-
matoid and other disease. Nat Med 1995; 1, 27±31.
2. Koch AE, Polverini PJ, Kunkel SL et al. Interleukin-
8 as a macrophage-derived mediator of angiogenesis.
Science 1992; 258, 1798±1801.
3. Carswell EA, Old LJ, Kassel RL et al. An endo-
toxin-induced serum factor that causes necrosis of
tumors. Proc Natl Acad Sci USA 1975; 72, 3666±
3670.
4. Schweigerer L, Malerstein B, Gospodarowicz D.
Tumor necrosis factor inhibits the proliferation of
cultured capillary endothelial cells. Biochem Biophys
Res Comm 1987; 143, 997±1004.
5. Frater-Schroder M, Risau W, Hallman R et al. Tumor
necrosis factor type a, a potent inhibitor of endothelial
cell growth in vitro, is angiogenic in vivo. Proc Natl
Acad Sci USA 1987; 84, 5277±5281.
6. Leibovich SJ, Polverini PJ, Shepard HM et al. Mac-
rophage-induced angiogenesis is mediated by tumor
necrosis factor-a. Nature 1987; 329, 630±632.
7. Fajardo LF, Kwan HH, Kowalski J et al. Dual role of
tumor necrosis factor-a in angiogenesis. Am J Pathol
1992; 140, 539±544.
8. Montrucchio G, Lupia E, Battaglia E et al. Tumor
necrosis factor a-induced angiogenesis depends on in
situ platelet-activating factor biosynthesis. J Exp Med
1994; 180, 377±382.
9. Pandey A, Shao H, Marks RM et al. Role of B61, the
ligand for the Eck receptor tyrosine kinase, in TNF-
a-induced angiogenesis. Science 1995; 268, 567±569.
10. Yoshida S, Ono M, Shono T et al. Involvement of
interleukin-8, vascular endothelial growth factor, and
basic ®broblast growth factor in tumor necrosis factor
alpha-dependent angiogenesis. Mol Cell Biol 1997;
17, 4015±4023.
11. Friedlander M, Brooks PC, Shaffer RW et al. De®-
nition of two angiogenic pathways by distinct av
integrins. Science 1995; 270, 1500±1502.
12. Osborn L, Hession C, Tizard R et al. Direct expres-
sion cloning of vascular cell adhesion molecule 1, a
cytokine-induced endothelial protein that binds to
lymphocytes. Cell 1989; 59, 1203±1211.
13. Bevilacqua MP, Stengelin S, Gimbrone MA, Seed B.
Endothelial leukocyte adhesion molecule 1: an in-
ducible receptor for neutrophils related to comple-
ment regulatory proteins and lectins. Science 1989;
243, 1160±1165.
14. Koch AE, Halloran MM, Haskell CJ et al. Angio-
genesis mediated by soluble forms of E-selectin and
vascular cell adhesion molecule-1. Nature 1995; 376,
517±519.
15. Elices MJ, Osborn L, Takada Y et al. VCAM-1 on
activated endothelium interacts with the leukocyte
Angiogenesis induced by TNF-a is mediated by a4 integrins
Angiogenesis á Vol 2 á No 3 á 1998 273
integin VLA-4/®bronectin binding site. Cell 1990;
69, 577±584.
16. Ruegg C, Postigo AA, Sikorski EE et al. Role of
integrin a4b7/a4bP in lymphocyte adherence to
®bronectin and VCAM-1 and in homotypic cell
clustering. J Cell Biol 1992; 117, 179±189.
17. Massia SP, Hubbell JA. Vascular endothelial cell
adhesion and spreading promoted by the peptide
REDV of the IIICS region of plasma ®bronectin is
mediated by integrin a4b1. J Biol Chem 1992; 267,
14019±14026.
18. Vanderslice P, Ren K, Revelle JK et al. A cyclic
hexapeptide is a potent antagonist of a4 integrins.
J Immunol 1997; 158, 1710±1718.
19. Morbidelli L, Orlando C, Maggi CA et al. Prolif-
eration and migration of endothelial cells is pro-
moted by endothelins via activation of EtB
receptors. Am J Physiol 1995; 269, H686±H695.
20. Revelle BM, Scott D, Beck PJ. Single amino acid
residues in the E- and P-selectin epidermal growth
factor domains can determine carbohydrate binding
speci®city. J Biol Chem 1996; 271, 16160±16170.
21. Melder RJ, Koenig GC, Witwer BP et al. During
angiogenesis, vascular endothelial growth factor and
basic ®broblast growth factor regulate natural killer
cell adhesion to tumor endothelium. Nat Med 1996;
2, 992±997.
22. Robaye R, Mosselmans R, Fiers W, Dumont JE.
Tumor necrosis factor induces apoptosis (pro-
grammed cell death) in normal endothelial cells `in
vitro'. Am J Pathol 1991; 138, 447±453.
23. Blystone SD, Lindberg FP, LaFlamme SE, Brown EJ.
Integrin avb3 differentially regulates adhesive and
phagocytic functions of the ®bronectin receptor
a5b1. J Cell Biol 1994; 127, 1129±1137.
24. Woodside DG, Teague TK, McIntyre BW. Speci®c
inhibition of T lymphocyte coactivation by trigger-
ing integrin b1 reveals convergence of b1, b2, and b7
signaling pathways. J Immunol 1996; 157, 700±706.
25. Diaz-Gonzalez F, Forsyth J, Steiner B, Ginsberg MH.
Trans-dominant inhibition of integrin function. Mol
Biol Cell 1996; 7, 1939±1951.
26. Porter JC, Hogg N. Integrin cross talk: activation of
lymphocyte function-associated antigen-1 on human
T cells alters a4b1 and a5b1-mediated function.
J Cell Biol 1997; 138, 1437±1447.
27. Imhof BA, Weerasinghe D, Brown EJ et al. Cross
talk between avb3 and a4b1 integrins regulates
lymphocyte migration on vascular cell adhesion
molecule 1. Eur J Immunol 1997; 27, 3242±3252.
28. Huhtala P, Humpheries MJ, McCarthy JB et al.
Cooperative signaling by a5b1 and a4b1 integrins
regulates metalloproteinase gene expression in ®-
broblasts adhering to ®bronectin. J Cell Biol 1995;
129, 867±879.
29. van Hinsbergh VWM, van den Berg EA, Fiers W,
Dooijewaard G. Tumor necrosis factor induces the
production of urokinase-type plasminogen activator
by human endothelial cells. Blood 1990; 75, 1991±
1998.
30. Wei Y, Lukashev M, Simon DI et al. Regulation of
integrin function by the urokinase receptor. Science
1996; 273, 1551±1554.
31. Lobb RR, Hemler ME. The physiological role of a4
integrins in vivo. J Clin Invest 1994; 94, 1722±1728.
32. Abraham WM, Seilczak MW, Ahmed A et al. a4-
integrins mediate antigen-induced late bronchial re-
sponses and prolonged airway hyperresponsiveness in
sheep. J Clin Invest 1994; 93, 776±787.
33. Yednock TA, Cannon C, Fritz LC et al. Prevention of
experimental autoimmune encephalomyelitis by an-
tibodies against a4b1 integrin. Nature 1992; 356,
63±66.
34. Baron JL, Reich E, Visintin I, Janeway CA. The
pathogenesis of adoptive murine autoimmune dia-
betes requires an interaction between a4-integrins
and vascular cell adhesion molecule-1. J Clin Invest
1994; 93, 1700±1708.
35. Burkly LC, Jakubowski A, Hattori M. Protection
against adoptive transfer of autoimmune diabetes
mediated through very late antigen-4 integrin. Di-
abetes 1994; 43, 529±534.
36. Podolsky DK, Lobb R, King N et al. Attenuation of
colitis in the cotton-top tamarin by anti-a4 integrin
monoclonal antibody. J Clin Invest 1993; 92, 372±
380.
37. Isobe M, Suzuki J, Yagita H et al. Immunosuppres-
sion to cardiac allografts and soluble antigens by
anti-VCAM-1 and anti-VLA-4 monoclonal antibod-
ies. J Immunol 1994; 153, 5810±5818.
38. Issekutz AC, Ayer L, Miyasaka M, Issekutz TB.
Treatment of established adjuvant arthritis in rats
with monoclonal antibody to CD18 and very late
activation antigen-4 integrins suppresses neutrophil
and T-lymphocyte migration to the joints and im-
proves clinical disease. Immunology 1996; 88, 569±
576.
39. Seiffge D. Protective effects of monoclonal antibody
to VLA-4 on leukocyte adhesion and course of disease
in adjuvant arthritis in rats. J Rheum 1996; 23,
2086±2091.
40. Scott DL, Willoughby DA, Blake DR. Molecular
insights into rheumatoid arthritis. Mol Aspects Med
1991; 12, 341±394.
41. Moreland LW, Baumgartner SW, Schiff MH et al.
Treatment of rheumatoid arthritis with recombinant
human tumor necrosis factor receptor (p75)-Fc fusion
protein. N Engl J Med 1997; 337, 141±147.
42. Koch AE, Burrows JC, Haines GK et al. Immuno-
localization of endothelial and leukocyte adhesion
P. Vanderslice et al.
274 Angiogenesis á Vol 2 á No 3 á 1998
molecules in human rheumatoid and osteo arthritic
synovial tissues. Lab Invest 1991; 64, 313±320.
43. Morales-Ducret J, Wayner E, Elices MJ et al. Alpha
4/beta 1 integrin (VLA-4) ligands in arthritis. Vas-
cular cell adhesion molecule-1 expression in syno-
vium and on ®broblast-like synoviocytes. J Immunol
1992; 149, 1424±1431.
44. Wellicome SM, Kapahi P, Mason JC et al. Detection
of a circulating form of vascular cell adhesion mol-
ecule-1: raised levels in rheumatoid arthritis and
systemic lupus erythematosus. Clin Exp Immunol
1993; 92, 412±418.
45. Mason JC, Kapahi P, Haskard DO. Detection of
increased levels of circulating ICAM-1 in some pa-
tients with rheumatoid arthritis but not in patients
with systemic lupus erythematosus. Lack of correla-
tion with levels of circulating VCAM-1. Arthritis
Rheum 1993; 36, 519±527.
Angiogenesis induced by TNF-a is mediated by a4 integrins
Angiogenesis á Vol 2 á No 3 á 1998 275
